Key Takeaways
Extended Takeaways
- Negative symptom improvement accrued beyond the acute phase: LS mean changes in PANSS Negative Subscale and Marder Negative Factor scores were −4.1 (0.24) and −4.5 (0.24) at week 4, improving further to −7.6 (0.35) and −8.2 (0.35) at week 56.
- Patients with higher baseline negative symptom burden showed larger absolute gains, with the prominent negative symptoms subgroup (n = 186) improving by −8.7 (0.44) on the PANSS Negative Subscale and −9.6 (0.44) on the Marder Negative Factor by week 56.
- Improvement was also seen in patients with predominantly negative symptoms at baseline, defined by high negative symptoms plus a PANSS Mohr Positive Factor score ≤19; in this subgroup (n = 48), LS mean change in Marder Negative Factor score reached −8.9 (0.78) at week 56.
- The week 56 changes exceeded anchor-based minimal improvement thresholds cited in the discussion for negative symptoms, including −3.8 and −5.0 on the Marder Negative Factor and −5.0 on the PANSS Negative Symptoms Subscale, supporting potential clinical meaningfulness of the observed score reductions.
- Interpret results cautiously because the 52-week extension had no placebo or active comparator, and data from the OLZ/SAM, placebo, and olanzapine groups during weeks 1–4 were pooled, preventing direct estimation of the OLZ/SAM-specific effect in the acute phase.
- This cohort began markedly symptomatic overall, with a mean (SD) PANSS Total score of 101.7 (11.1) and mean (SD) baseline Marder Negative Factor score of 25.2 (4.6), which is important when judging applicability to stable outpatient populations with less acute illness.
